PMID- 15085466
OWN - NLM
STAT- MEDLINE
DCOM- 20050331
LR  - 20181130
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 30 Suppl 1
DP  - 2004 Feb
TI  - Laboratory analysis of blood samples from patients treated with tinzaparin.
PG  - 49-55
AB  - Tinzaparin at two dosages, 175 anti-Xa U/kg subcutaneously administered for 7 
      days, followed by warfarin, and 175 anti-Xa U/kg subcutaneously given for 90 days 
      was compared with continuous intravenous unfractionated heparin (UFH) for 5 days, 
      followed by warfarin for 3 months, were tested in the treatment of patients with 
      proximal deep vein thrombosis. Several laboratory assays were used to monitor the 
      effects of tinzaparin and UFH. The tinzaparin only study arm produced a 4- to 
      6-second prolongation of the activated partial thromboplastin time (aPTT). 
      However, in the anti-Xa chromogenic assay and the Heptest assays, there was a 
      prolongation after the administration of all three agents. In the two groups 
      treated for 7 days, the anti-Xa and Heptest values returned to baseline after 
      cessation of therapy. In the patients treated with tinzaparin for 90 days, the 
      anti-Xa and Heptest remained elevated throughout the treatment period. The 
      anti-IIa (anti-thrombin) results were considerably lower values in the 
      tinzaparin-treated groups. Tissue factor pathway inhibitor (TFPI) antigen levels 
      were elevated 2- to 2.5-fold in all three groups. In addition, the 
      thrombin/antithrombin (TAT) complexes were also measured. After treatment, the 
      TAT levels decreased over time. Tinzaparin was more effective in decreasing these 
      levels. These results suggest that both Heptest and anti-Xa assays can be used to 
      monitor patients receiving tinzaparin. TAT may be a useful test in monitoring the 
      resolution of the clots. However, additional clinical validation is required to 
      demonstrate the relevance of these parameters with the clinical outcome.
FAU - Hoppensteadt, Debra A
AU  - Hoppensteadt DA
AD  - Departments of Pathology and Pharmacology, Loyola University Chicago, Maywood, 
      Illinois, USA. dhoppen@lumc.edu
FAU - Willows, Louise
AU  - Willows L
FAU - Leitz, Helen
AU  - Leitz H
FAU - Nicolaides, Andrew
AU  - Nicolaides A
FAU - Fareed, Jawed
AU  - Fareed J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Biomarkers)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Lipoproteins)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 7UQ7X4Y489 (Tinzaparin)
RN  - 9001-26-7 (Prothrombin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Biomarkers/blood
MH  - Drug Administration Schedule
MH  - Drug Monitoring/methods
MH  - Factor Xa Inhibitors
MH  - Heparin/administration & dosage
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Lipoproteins/blood
MH  - Partial Thromboplastin Time
MH  - Prothrombin/antagonists & inhibitors
MH  - Time
MH  - Tinzaparin
MH  - Venous Thrombosis/*drug therapy
MH  - Warfarin/administration & dosage
EDAT- 2004/04/16 05:00
MHDA- 2005/04/01 09:00
CRDT- 2004/04/16 05:00
PHST- 2004/04/16 05:00 [pubmed]
PHST- 2005/04/01 09:00 [medline]
PHST- 2004/04/16 05:00 [entrez]
AID - 10.1055/s-2004-823003 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2004 Feb;30 Suppl 1:49-55. doi: 10.1055/s-2004-823003.